Agenus Inc. (AGEN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Agenus Inc. (AGEN) closed at USD 6.68 on 2026-10-15, a change of +73.5 % over the past year, with a market capitalization of USD 272.78M.

Agenus Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Agenus Inc. key figures

Previous close

USD 6.68 (2026-10-15)

1-year change

+73.5 %

Market cap

USD 272.78M

Enterprise value

USD 287.12M

P/E ratio (trailing)

2.39

P/E ratio (forward)

-54.91

EPS (trailing)

2.53

EPS (forward)

-0.11

PEG ratio

1.44

Price to book

-1.29

Revenue growth

34.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.51

Employees

81

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Agenus Inc.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Agenus Inc. and compare it with other stocks.